News 2020-05-13
Porton Shanghai Formulation R&D Center Launched Construction
Shanghai, China, May 13, 2020 - Porton Pharmatech Co. ,Ltd. (Porton Pharmatech), a subsidiary of Porton Pharma Solutions Ltd. (Porton, Stock Code: 300363), today announced the commencement of construction of its Shanghai R&D Center, which would be Porton’s third formulation lab site that has been constructed since 2019. It has previously started design and construction of two other formulation labs based in Chongqing, China and New Jersey，USA.
Others
More
News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.
News 2026-10-16
Porton Achieves Third-Party Verification for Its First Commercial Product LCA and PCF Study
Conducted in accordance with ISO 14040:2006 and ISO 14044:2006 (Life Cycle Assessment) and ISO 14067:2018 (Product Carbon Footprint) standards, the study employs a cradle-to-gate system boundary, marking the formal extension of Porton's ESG management from the organizational level to the product level.
